Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
At 12mg weekly, the maximum studied dose, mean weight reduction hit 24.2% in Phase 2 and 28.7% in Phase 3 (TRIUMPH-4)
Unlike older therapies, tirzepatide simultaneously engages both GLP-1 and GIP pathways, leading to reduced hunger, prolonged satisfaction, improved insulin response, and potential increased calorie burn
Choosing the Right GLP-1 Medication Choosing the right GLP-1 receptor agonist can significantly impact the management of Type 2 Diabetes and/or obesity
Questions to ask: Dosing and administration: How do I take the Wegovy pill correctly, and what if I miss a dose
This is a clinically important point that is frequently underexplained to patients
Researchers comparing semaglutide against newer multi-agonists should consult the retatrutide vs semaglutide vs tirzepatide reference for receptor-selectivity context
